Bio-Lab, Inc. v. United States

435 F. Supp. 3d 1361, 2020 CIT 45
United States Court of International Trade·Decided April 7, 2020·No. 18-00155·Published·Cited by 2 cases

Opinion

Slip Op. 20–

UNITED STATES COURT OF INTERNATIONAL TRADE

:

BIO-LAB, INC., CLEARON CORP. and : OCCIDENTAL CHEMICAL CORP., :

:

Plaintiffs, :

: Before: Richard K. Eaton, Judge v. :

: Court No. 18-00155

UNITED STATES, :

:

Defendant, :

:

and :

:

JUANCHENG KANGTAI CHEMICAL CO., LTD. : and HEZE HUAYI CHEMICAL CO., LTD., :

:

Defendant-Intervenors. :

__________________________________________:

OPINION

[United States Department of Commerce’s Final Results are sustained.]

Dated$SULO

James R. Cannon, Jr., Cassidy Levy Kent (USA) LLP, of Washington, DC, argued for Plaintiffs. With him on the brief was Ulrika K. Swanson.

Sonia M. Orfield, Trial Attorney, Commercial Litigation Branch, Civil Division, U.S.

Department of Justice, of Washington, DC, argued for Defendant. With her on the brief were Joseph H. Hunt, Acting Assistant Attorney General, Jeanne E. Davidson, Director, and Patricia M. McCarthy, Assistant Director. Of counsel on the brief was Catherine Miller, Attorney, Office of the Chief Counsel for Import Administration, U.S. Department of Commerce, of Washington, DC.

Gregory S. Menegaz, deKieffer & Horgan, PLLC, of Washington, DC, argued for Defendant-Intervenors. With him on the brief were J. Kevin Horgan and Alexandra H. Salzman.

Court No. 18-00155 Page 2

Eaton, Judge: Bio-Lab, Inc., Clearon Corp., and Occidental Chemical Corp. (“Plaintiffs”)

are U.S. domestic producers of chlorinated isocyanurates1 and the petitioners in this proceeding. They challenge the United States Department of Commerce’s (“Commerce” or the “Department”) final results published in Chlorinated Isocyanurates From the People’s Republic of China, 83 Fed. Reg. 26,954 (Dep’t Commerce June 11, 2018) (“Final Results”), and the accompanying Issues and Decision Mem. (June 5, 2018), P.R. 72 (“Final IDM”).

In the Final Results, Commerce determined that Defendant-Intervenors and mandatory respondents Juancheng Kangtai Chemical Co., Ltd. (“Kangtai”) and Heze Huayi Chemical Co., Ltd. (“Heze”), Chinese producers and exporters of the chemicals, received countervailable subsidies during the period of review, including through a loan program called the Export Buyer’s Credit Program.2 See Final IDM at 1. It made this determination on the basis of adverse inferences, having found that the use of adverse facts available (“AFA”)3 was warranted because the

1 Chlorinated isocyanurates, the subject chemicals, are “derivatives of cyanuric acid, described as chlorinated s-triazine triones” that are used for, among other things, water treatment. See Final IDM at 2; Chlorinated Isocyanurates from the People’s Rep. of China, 79 Fed. Reg. 67,424 (Dep’t Commerce Nov. 13, 2014) (countervailing duty order).

2 The Export Buyer’s Credit Program provides credit at preferential rates to foreign purchasers of goods exported by Chinese companies in order to promote exports. See Clearon Corp. v. United States, 43 CIT __, 359 F. Supp. 3d 1344, 1347 (2019). The program has been the subject of much litigation before this Court. See, e.g., Yama Ribbons & Bows Co. v. United States, No. 18-00054, 2019 WL 7373856, at *7 n.7 (CIT Dec. 30, 2019) (collecting cases).

3 Before Commerce may use AFA, it must make two separate findings. First, Commerce shall use facts available “[i]f . . . necessary information is not available on the record, or . . . an interested party or any other person . . . fails to provide . . . information [that has been requested by Commerce] . . . in the form and manner requested,” or “significantly impedes” a proceeding. 19 U.S.C. § 1677e(a)(1)-(2)(B), (C). Second, if Commerce determines that the use of facts available is warranted, it must make the requisite additional finding that “an interested party has failed to cooperate by not acting to the best of its ability to comply with a request for information” before it may use an adverse inference “in selecting from among the facts otherwise available.” Id. § 1677e(b)(1).

Court No. 18-00155 Page 3

Government of China (1) failed to provide necessary information about the operation of the Export Buyer’s Credit Program, and (2) failed to act to the best of its ability to cooperate with Commerce’s requests for information about the program.4 See 19 U.S.C. § 1677e(a), (b); Final IDM at 5-6. To determine an AFA rate for the Export Buyer’s Credit Program, Commerce used a hierarchy it developed for administrative reviews. See 19 U.S.C. § 1677e(d).5 Applying step two of the hierarchy, the Department selected the rate of 0.87 percent ad valorem as a component of the final subsidy rate calculated for Kangtai and Heze. See Final IDM at 12. This rate had previously been determined in an earlier segment of the same proceeding for a Chinese government loan program called the Export Seller’s Credit Program. Commerce found the Export Seller’s Credit Program to be “similar” to the Export Buyer’s Credit Program because each conferred a similar benefit: access to government-subsidized loans. See Final IDM at 12; 19 U.S.C. § 1677e(d)(1)(A)(i) (emphasis added) (permitting Commerce to “use a countervailable subsidy rate applied for the same or similar program in a countervailing duty proceeding involving the same country”).

Quite naturally, Plaintiffs do not question Commerce’s finding that the use of AFA was warranted. Nor do Plaintiffs dispute the lawfulness of the hierarchy that Commerce used to select an AFA rate for the Export Buyer’s Credit Program. Rather, they argue that the hierarchy, as

4 It is worth noting that, while the Department found that the respondents benefitted from the Export Buyer’s Credit Program, based on AFA, the only evidence on the record regarding use is that the respondents’ U.S. customers did not use the program. See Kangtai’s Sec. III Quest. Resp. (Apr. 12, 2017), Ex. 15, C.R. 15; Heze’s Sec. III Quest. Resp. (Apr. 12, 2017), Ex. 12, C.R. 7.

5 In pertinent part, this subsection provides that if Commerce “uses an inference that is adverse to the interests of a party under [19 U.S.C. § 1677e(b)(1)(A)] in selecting among the facts otherwise available,” Commerce “may . . . in the case of a countervailing duty proceeding . . . (i) use a countervailable subsidy rate applied for the same or similar program in a countervailing duty proceeding involving the same country; or (ii) if there is no same or similar program, use a countervailable subsidy rate for a subsidy program from a proceeding that [Commerce] considers reasonable to use.” 19 U.S.C. § 1677e(d)(1).

Court No. 18-00155 Page 4

applied here, resulted in a rate for the program that is “simply too low to induce” the Government of China to cooperate with Commerce’s requests for information in the future. See Pls.’ Reply Br. Supp. Mot. J. Admin. R., ECF No. 37, 6; Pls.’ Mem. Supp. Mot. J. Admin. R., ECF No. 26-1 (“Pls.’ Br.”) 3. Thus, for Plaintiffs, the rate fails to satisfy the purpose of the AFA statute and, therefore, is contrary to law. See Pls.’ Br. 3; 19 U.S.C. § 1677e(b). In addition, Plaintiffs claim that substantial record evidence does not support the finding that the Export Buyer’s Credit Program and the Export Seller’s Credit Program are “similar.” See Pls.’ Br. 3. As a result, they ask the court to “remand [this case] to [Commerce] with instructions to reconsider [these] issues and address specifically the rationale for relying on a 0.87 percent subsidy rate rather than a higher rate and the reasons for finding that Export Buyer’s Credits and Export Seller’s Credits are ‘similar’ for purpose of applying adverse inferences pursuant to the statute.” Pls.’ Br. 20.

For their part, Defendant the United States (“Defendant”), on behalf of Commerce, and Defendant-Intervenors Kangtai and Heze ask the court to sustain the Final Results. See Def.’s Resp. Pls.’ Mot. J. Agency R., ECF No. 34 (“Def.’s Br.”); see also Def.-Ints.’ Resp., ECF No. 33.

Free access — add to your briefcase to read the full text and ask questions with AI

Bio-Lab, Inc. v. United States, 435 F. Supp. 3d 1361, 2020 CIT 45 (cit 2020).

435 F. Supp. 3d 1361 (Bio-Lab, Inc. v. United States) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bio-Lab, Inc. v. United States
487 F. Supp. 3d 1291 (Court of International Trade, 2020)
Clearon Corp. v. United States
474 F. Supp. 3d 1339 (Court of International Trade, 2020)